Glioma
IDH-mutant astrocytoma and oligodendroglioma, IDH inhibitors, and BRAF- and H3-altered tumours.
Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.
- PaperNeurocognitive function and quality of life results from a phase II study (NRG/RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas.
Wefel JS, Pugh SL, Choucair AK et al. International journal of radiation oncology, biology, physics.
- New trialNew Ph2 trial: NCT07916389
St. Jude Children's Research Hospital. Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
- New trialNew Ph3 trial: NCT07912398
Hutchmed. HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
- Readout dueReadout due: hSTAR GBM reached primary completion
Leland Metheny. hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- Readout dueReadout due: NANO-GBM reached primary completion
Centre Jean Perrin. AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
- Readout dueReadout due: NCT03510208 reached primary completion
Stanford University. Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- Readout dueReadout due: NCT05734560 reached primary completion
Darell Bigner. D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
- Readout dueReadout due: STAR-GBM reached primary completion
Myosin Therapeutics Inc.. A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
- Phase advanceSRN-101 advances to Ph1/Ph2 (indication level)
Siren Biotechnology posted ALERT-1: A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)
- Readout dueReadout due: NCT03952598 reached primary completion
National Cancer Institute (NCI). Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
- PaperContrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial.
Goplen D, Rahman MA, Brekke J et al. Biomarker research.
- New trialNew Ph2 trial: NCT07891286
National Cancer Institute (NCI). Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
- Results postedResults posted: NCT03904862
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
- New trialNew Ph1 trial: iVOCAL (NCT07877415)
Heidelberg University. A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)
- PaperEGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.
Chandramohan V, Herndon JE 2nd, Barnwal A et al. Nature medicine.
- Paper
- PaperVolumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT).
Singnurkar A, Sahgal A, Lechtman E et al. Journal of neuro-oncology.
- PaperFine-tuning the beam: Biomarker-guided radiation strategies in the evolving management of isocitrate dehydrogenase (IDH)-mutant glioma.
Marciscano AE, Shih HA, Niyazi M. Neuro-oncology.
- PaperTriptolide as a multi-target anticancer agent: molecular mechanisms and translational potential.
Shadin M, Shakil Hossain M, Mandal S et al. Naunyn-Schmiedeberg's archives of pharmacology.
- Readout dueReadout due: NCT04201457 reached primary completion
Pediatric Brain Tumor Consortium. A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
- PaperPhase Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure.
Schreck KC, Lal B, Zhou J et al. Cancer research communications.
- Readout dueReadout due: SUR-CAN reached primary completion
Centre Oscar Lambret. Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
- Readout dueReadout due: AFGBMBiop reached primary completion
Peter Siesjö. Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
- Readout dueReadout due: NCT04094610 reached primary completion
Turning Point Therapeutics, Inc.. A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Readout dueReadout due: SOLID reached primary completion
University Health Network, Toronto. Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
- Readout dueReadout due: NCT05986851 reached primary completion
Cantex Pharmaceuticals. Azeliragon in MGMT Unmethylated Glioblastoma
- Paper
- PaperTozuleristide Fluorescence-Guided Resection of Gliomas: Results of a Phase II Investigator-Initiated Study.
Fox RC, Fan X, Mamelak AN et al. Operative neurosurgery (Hagerstown, Md.).
- Readout dueReadout due: NCT04049669 reached primary completion
Theodore S. Johnson. Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
- Readout dueReadout due: NCT06750458 reached primary completion
Tanta University. Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients
- PaperEmerging role of targeted therapy in drug-resistant epilepsy in patients with glioma.
Bruno F, Pellerino A, Rudà R. Current opinion in oncology.
- PaperSafety and efficacy of sonodynamic therapy combined with Stupp regimen in controlling postoperative residual lesions of glioblastoma: A prospective pilot phase I study.
Wang L, Ding J, Liu X et al. Photodiagnosis and photodynamic therapy.
- PaperNeoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.
Sun L, Markus LF, Sanchez JC et al. Nature communications.
- Readout dueReadout due: NCT05465954 reached primary completion
Mayo Clinic. Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- PaperEfficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF(V600E)- or BRAF(InsT)-Mutant Brain Tumors: PNOC002.
Nicolaides T, Hoogendijk R, Jaeger-Krause M et al. JCO precision oncology.
- Readout dueReadout due: NCT05607407 reached primary completion
Case Comprehensive Cancer Center. Methimazole in Patients With Progressive Glioblastoma
- Readout dueReadout due: NCT05077735 reached primary completion
Mayo Clinic. Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial
- Readout dueReadout due: NCT04752813 reached primary completion
BPGbio. A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
- Readout dueReadout due: NCT05183204 reached primary completion
Weill Medical College of Cornell University. Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
- Paper
- Phase advanceEGFR/EGFRvIII Inhibitor WSD0922-FU advances to Ph2 (indication level)
Mayo Clinic posted NCT07708961: Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.